Saumini Srinivasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Saumini Srinivasan has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Anne Bergeron
Division of Pulmonology, Geneva University Hospitals (HUG), 1205 Geneva, Switzerland
2 shared publications - Ajay Sheshadri
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
1 shared publication - Ali Y. Suliman
Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, USA
1 shared publication - Alicia Casey
Department of Pediatrics, Division of Pulmonary Medicine, Boston Children’s Hospital , Boston, MA
1 shared publication - Aliva De
Division of Pediatric Pulmonology, Columbia University Irving Medical Center, New York, NY 10032, USA
1 shared publication - Amanda Cole
Department of Infectious Diseases St. Jude Children's Research Hospital Memphis Tennessee USA
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9) , e70467
Role of Respiratory Viral Infections in Airflow Obstruction After Hematopoietic Cell Transplantation
Background: Respiratory viral infections (RVIs) in allogeneic hematopoietic cell transplant (allo‐HCT) recipients can cause airflow obstruction (AFO). Despite this risk, the impact of community‐acquired RVI on PFTs in pediatric patients after allo‐HCT remains unclear. Objective: The study determines the role of RVI in the development of AFO post‐transplant among survivors of allo‐HCT. Study Design: This retrospective study analyzed St. Jude patients undergoing allo‐HCT between 2003–2020. AFO was defined by z ‐scores and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio expressed as lower limit of normal (LLN). Baseline parameters were obtained before allo‐HCT, and Year 1 parameters within 425 days post allo‐HCT. Spirometry measures were calculated using the global lung function Initiative (GLI) calculator. Bivariate and multivariate logistic regression identified risk factors for AFO following allo‐HCT. Results: A total of 397 patients were included, with a median age of 12.7 years. RVI occurred in 13% of patients within the first 100 days after transplantation. AFO developed in 12% of patients. Among those with AFO, 68% had a baseline FEV1/FVC ratio above the LLN, and 11% had a history of lower respiratory tract infection (LRTI) ( p < 0.05). The median time from transplant to RVI was shorter in patients with AFO (12 vs. 34 days). A baseline LLN value was a significant predictor of AFO. However, after adjusting for known covariates, RVI was not independently associated with AFO risk. Conclusion: RVIs within 100 days of allo‐HCT did not significantly affect AFO following transplant in pediatric patients.
- 25 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9) , e70467
Open AccessRole of Respiratory Viral Infections in Airflow Obstruction After Hematopoietic Cell Transplantation
Background: Respiratory viral infections (RVIs) in allogeneic hematopoietic cell transplant (allo‐HCT) recipients can cause airflow obstruction (AFO). Despite this risk, the impact of community‐acquired RVI on PFTs in pediatric patients after allo‐HCT remains unclear. Objective: The study determines the role of RVI in the development of AFO post‐transplant among survivors of allo‐HCT. Study Design: This retrospective study analyzed St. Jude patients undergoing allo‐HCT between 2003–2020. AFO was defined by z ‐scores and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio expressed as lower limit of normal (LLN). Baseline parameters were obtained before allo‐HCT, and Year 1 parameters within 425 days post allo‐HCT. Spirometry measures were calculated using the global lung function Initiative (GLI) calculator. Bivariate and multivariate logistic regression identified risk factors for AFO following allo‐HCT. Results: A total of 397 patients were included, with a median age of 12.7 years. RVI occurred in 13% of patients within the first 100 days after transplantation. AFO developed in 12% of patients. Among those with AFO, 68% had a baseline FEV1/FVC ratio above the LLN, and 11% had a history of lower respiratory tract infection (LRTI) ( p < 0.05). The median time from transplant to RVI was shorter in patients with AFO (12 vs. 34 days). A baseline LLN value was a significant predictor of AFO. However, after adjusting for known covariates, RVI was not independently associated with AFO risk. Conclusion: RVIs within 100 days of allo‐HCT did not significantly affect AFO following transplant in pediatric patients.
- Open Access
- 1 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (3) , 262-280
Detection of Bronchiolitis Obliterans Syndrome after Pediatric Hematopoietic Stem Cell Transplantation: An Official American Thoracic Society Clinical Practice Guideline
Background: Many children undergo allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of malignant and nonmalignant conditions. Unfortunately, pulmonary complications occur frequently post-HSCT, with bronchiolitis obliterans syndrome (BOS) being the most common noninfectious pulmonary complication. Current international guidelines contain conflicting recommendations regarding post-HSCT surveillance for BOS, and a recent NIH workshop highlighted the need for a standardized approach to post-HSCT monitoring. As such, this guideline provides an evidence-based approach to detection of post-HSCT BOS in children. Methods: A multinational, multidisciplinary panel of experts identified six questions regarding surveillance for, and evaluation of, post-HSCT BOS in children. A systematic review of the literature was undertaken to answer each question. The Grading of Recommendations, Assessment, Development, and Evaluation approach was used to rate the quality of evidence and the strength of recommendations. Results: The panel members considered the strength of each recommendation and evaluated the benefits and risks of applying the intervention. In formulating the recommendations, the panel considered patient and caregiver values, the cost of care, and feasibility. Recommendations addressing the role of screening pulmonary function testing and diagnostic tests in children with suspected post-HSCT BOS were made. Following a Delphi process, new diagnostic criteria for pediatric post-HSCT BOS were also proposed. Conclusions: This document provides an evidence-based approach to the detection of post-HSCT BOS in children while also highlighting considerations for the implementation of each recommendation. Further, the document describes important areas for future research.
- 1 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (3) , 262-280
Open AccessDetection of Bronchiolitis Obliterans Syndrome after Pediatric Hematopoietic Stem Cell Transplantation: An Official American Thoracic Society Clinical Practice Guideline
Background: Many children undergo allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of malignant and nonmalignant conditions. Unfortunately, pulmonary complications occur frequently post-HSCT, with bronchiolitis obliterans syndrome (BOS) being the most common noninfectious pulmonary complication. Current international guidelines contain conflicting recommendations regarding post-HSCT surveillance for BOS, and a recent NIH workshop highlighted the need for a standardized approach to post-HSCT monitoring. As such, this guideline provides an evidence-based approach to detection of post-HSCT BOS in children. Methods: A multinational, multidisciplinary panel of experts identified six questions regarding surveillance for, and evaluation of, post-HSCT BOS in children. A systematic review of the literature was undertaken to answer each question. The Grading of Recommendations, Assessment, Development, and Evaluation approach was used to rate the quality of evidence and the strength of recommendations. Results: The panel members considered the strength of each recommendation and evaluated the benefits and risks of applying the intervention. In formulating the recommendations, the panel considered patient and caregiver values, the cost of care, and feasibility. Recommendations addressing the role of screening pulmonary function testing and diagnostic tests in children with suspected post-HSCT BOS were made. Following a Delphi process, new diagnostic criteria for pediatric post-HSCT BOS were also proposed. Conclusions: This document provides an evidence-based approach to the detection of post-HSCT BOS in children while also highlighting considerations for the implementation of each recommendation. Further, the document describes important areas for future research.
- Open Access
Recommendations for surveillance of pulmonary dysfunction among childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary dysfunction. Current follow-up care guidelines are discordant. Therefore, the International Late Effects of Childhood Cancer Guideline Harmonization Group established and convened a panel of 33 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence regarding risk factors for pulmonary dysfunction, types of pulmonary function testing, and timings of surveillance, then we formulated our recommendations. We recommend that CAYA cancer survivors and healthcare providers are aware of reduced pulmonary function risks and pay vigilant attention to potential symptoms of pulmonary dysfunction, especially among survivors treated with allogeneic haematopoietic stem cell transplantation, thoracic radiotherapy, and thoracic surgery. Based on existing limited evidence, our panel currently recommends pulmonary function testing only for symptomatic survivors. Since scarce existing evidence informs our recommendation, we highlight the need for prospective collaborative studies to address pulmonary function knowledge gaps among CAYA cancer survivors.
Open AccessRecommendations for surveillance of pulmonary dysfunction among childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Childhood, adolescent, and young adult (CAYA) cancer survivors are at risk of pulmonary dysfunction. Current follow-up care guidelines are discordant. Therefore, the International Late Effects of Childhood Cancer Guideline Harmonization Group established and convened a panel of 33 experts to develop evidence-based surveillance guidelines. We critically reviewed available evidence regarding risk factors for pulmonary dysfunction, types of pulmonary function testing, and timings of surveillance, then we formulated our recommendations. We recommend that CAYA cancer survivors and healthcare providers are aware of reduced pulmonary function risks and pay vigilant attention to potential symptoms of pulmonary dysfunction, especially among survivors treated with allogeneic haematopoietic stem cell transplantation, thoracic radiotherapy, and thoracic surgery. Based on existing limited evidence, our panel currently recommends pulmonary function testing only for symptomatic survivors. Since scarce existing evidence informs our recommendation, we highlight the need for prospective collaborative studies to address pulmonary function knowledge gaps among CAYA cancer survivors.